BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc., (“CANbridge,” stock code 1228.HK) a leading China-based global…
PASADENA, Calif.–(BUSINESS WIRE)–$HLGN #ArtificialIntelligence–Heliogen, Inc. (“Heliogen” or the “Company”) (NYSE: HLGN), a leading provider of…
LOS ANGELES–(BUSINESS WIRE)–Adel Hagekhalil, general manager of the Metropolitan Water District of Southern California, issues…
Bagsværd, Denmark, 28 March 2022 – Novo Nordisk today announced that the US Food and Drug…
Regulated information March 28, 2022, 10:30 PM CETMarch 28, 2022, 4:30 PM ET Breda, the Netherlands /…
AUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…
Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple…
BOCA RATON, Fla., March 28, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First…
NEW YORK, NY, March 28, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo”…
Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy…
Mary Riley, J.D., appointed as general counsel Lisa Bowers, MHSA, and Mittie Doyle, M.D., FACR,…
-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First…
-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended…
Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022…
– Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 – REHOVOT,…
ERYTECH to Participate in the Upcoming April Investor Conferences Cambridge, MA (U.S.) and Lyon (France),…
Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers…
Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry…
Confirmed overall response rate improves to 41% at 100mg BID dose level Continued favorable safety…
Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs Progressed Company’s Targeted…